Rodman & Renshaw Maintain Market Outperform Rating and $12 PT on Alnylam Pharmaceuticals

A report from Rodman & Renshaw reiterates its Market Outperform rating and $12 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The report states, “The company expects to finish the year with more than $250mm in cash. We have made few changes to our financial model going forward... Overall, the company exhibited exemplary expense control in the quarter, as G&A costs barely grew on a year-over-year basis."

ALNY closed yesterday at $7.73.